C4 Therapeutics Stock Book Value Per Share
| CCCC Stock | USD 1.74 0.11 6.75% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess C4 Therapeutics' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. C4 Therapeutics Company Book Value Per Share Analysis
C4 Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current C4 Therapeutics Book Value Per Share | 3.06 X |
Most of C4 Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, C4 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of C4 Therapeutics is about 3.058 times. This is 279.88% lower than that of the Biotechnology sector and 101.23% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.84% higher than that of the company.
CCCC Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses C4 Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics of similar companies.C4 Therapeutics is currently under evaluation in book value per share category among its peers.
CCCC Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (2.96) % | ||||
| Operating Margin | (7.28) % | ||||
| Current Valuation | (55.6 M) | ||||
| Shares Outstanding | 71.01 M | ||||
| Shares Owned By Insiders | 11.50 % | ||||
| Shares Owned By Institutions | 91.48 % | ||||
| Number Of Shares Shorted | 7.73 M | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 3.47 X | ||||
| Revenue | 35.58 M | ||||
| Gross Profit | (75.05 M) | ||||
| EBITDA | (103.37 M) | ||||
| Net Income | (105.32 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 65.76 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | (65.16 M) | ||||
| Short Ratio | 8.03 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 16.07 | ||||
| Number Of Employees | 110 | ||||
| Beta | 3.12 | ||||
| Market Capitalization | 123.55 M | ||||
| Total Asset | 349.6 M | ||||
| Retained Earnings | (633.7 M) | ||||
| Working Capital | 212.59 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
| Net Asset | 349.6 M |
About C4 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze C4 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out C4 Therapeutics Piotroski F Score and C4 Therapeutics Altman Z Score analysis. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.